Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer
6359.0000 -14.00 (-0.22%)
NSE Nov 24, 2025 15:49 PM
Volume: 393.8K
 

6359.00
-0.22%
Emkay
Overall revenue came marginally ahead of estimate by ~5% at Rs10.8bn as against estimate of Rs10.4bn. Overall net income stood at Rs2.6bn as against estimate of Rs2.42bn, helped by significantly higher other income. The highlight of Q4FY18 was a 200/400bps qoq expansion in gross margin/EBITDA margin. The additional EBITDA margin expansion is a result of remediation costs fading away, which should completely normalize in the next 1-2 quarters. short-term growth outlook for DIVI's is uncertain given the possible paucity of capacity. Valuation also looks challenging for DIVI's given the stock's run-up in the past few months,...
Number of FII/FPI investors decreased from 990 to 897 in Sep 2025 qtr
More from Divi's Laboratories Ltd.
Recommended